BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27885271)

  • 1. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
    Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
    Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
    Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
    Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
    Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
    Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
    Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.
    Li L; Tan Y; Chen X; Xu Z; Yang S; Ren F; Guo H; Wang X; Chen Y; Li G; Wang H
    PLoS One; 2014; 9(11):e113088. PubMed ID: 25405759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
    Rücker FG; Russ AC; Cocciardi S; Kett H; Schlenk RF; Botzenhardt U; Langer C; Krauter J; Fröhling S; Schlegelberger B; Ganser A; Lichter P; Zenz T; Döhner H; Döhner K; Bullinger L
    Leukemia; 2013 Feb; 27(2):353-61. PubMed ID: 22810507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and new treatment approaches in TP53 mutated AML.
    Hunter AM; Sallman DA
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
    Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
    Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAM213A is linked to prognostic significance in acute myeloid leukemia through regulation of oxidative stress and myelopoiesis.
    Oh CK; Ha M; Han ME; Heo HJ; Myung K; Lee Y; Oh SO; Kim YH
    Hematol Oncol; 2020 Aug; 38(3):381-389. PubMed ID: 32124993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
    Barbosa K; Li S; Adams PD; Deshpande AJ
    Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice.
    Pourebrahim R; Montoya RH; Akiyama H; Ostermann L; Khazaei S; Muftuoglu M; Baran N; Zhao R; Lesluyes T; Liu B; Khoury JD; Gagea M; Van Loo P; Andreeff M
    Cell Rep Med; 2024 May; 5(5):101558. PubMed ID: 38733986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia.
    Xie J; Chen K; Han H; Dong Q; Wang W
    Curr Res Transl Med; 2022 Sep; 70(4):103347. PubMed ID: 35483237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
    Andreeff M; Kelly KR; Yee K; Assouline S; Strair R; Popplewell L; Bowen D; Martinelli G; Drummond MW; Vyas P; Kirschbaum M; Iyer SP; Ruvolo V; González GM; Huang X; Chen G; Graves B; Blotner S; Bridge P; Jukofsky L; Middleton S; Reckner M; Rueger R; Zhi J; Nichols G; Kojima K
    Clin Cancer Res; 2016 Feb; 22(4):868-76. PubMed ID: 26459177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
    Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
    BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Analyses of
    Wen XM; Xu ZJ; Jin Y; Xia PH; Ma JC; Qian W; Lin J; Qian J
    Front Immunol; 2021; 12():717527. PubMed ID: 34745095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.